Pure Global

Study of ACR246 in Advanced Solid Tumors - Trial NCT06238401

Access comprehensive clinical trial information for NCT06238401 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hangzhou Adcoris Biopharmacy Co., Ltd and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 77 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06238401
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06238401
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of ACR246 in Advanced Solid Tumors
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase I/II.a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors

Study Focus

Advanced Solid Tumors

ACR246 for injection

Interventional

drug

Sponsor & Location

Hangzhou Adcoris Biopharmacy Co., Ltd

Timeline & Enrollment

Phase 1

Mar 01, 2024

Jan 01, 2026

77 participants

Primary Outcome

Safety and tolerability:

Summary

The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with
 advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended
 dose (RP2D) of ACR246.

ICD-10 Classifications

Malignant neoplasm: Prepuce
Carcinoma in situ, unspecified
Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm: Parametrium
Malignant neoplasm: Orbit

Data Source

ClinicalTrials.gov

NCT06238401

Non-Device Trial